OncoMatch/Clinical Trials/NCT04282187
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Is NCT04282187 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Decitabine and Ruxolitinib for acute myeloid leukemia.
Treatment: Decitabine · Ruxolitinib · Fedratinib · Pacritinib — This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ruxolitinib, fedratinib, and pacritinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a donor hematopoietic stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells. Decitabine, with ruxolitinib, fedratinib, or pacritinib may work better than multi-agent chemotherapy or no pre-transplant therapy, in treating patients with accelerated/blast phase myeloproliferative neoplasms.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myeloproliferative Neoplasm
Myelodysplastic Syndrome
Disease stage
Required: Stage ACCELERATED PHASE, BLAST PHASE
Performance status
ECOG OR KARNOFSKY 0–2
Prior therapy
Cannot have received: chemotherapy (e.g. hypomethylating agents or cytarabine-based regimens)
Exception: Prior temporary measures to control blood counts is allowed. Prior treatment with hydroxyurea, interferons or JAK inhibitor therapy is allowed
Previous treatment with chemotherapy (e.g. hypomethylating agents or cytarabine-based regimens) for MPN with >= 5% blasts in the blood or marrow. Prior temporary measures to control blood counts is allowed. Prior treatment with hydroxyurea, interferons or JAK inhibitor therapy is allowed
Cannot have received: anti-MDS/leukemia investigational agent
Treatment with any other anti-MDS/leukemia investigational agent within 2 weeks of start of study drugs
Lab requirements
Kidney function
Serum creatinine clearance >= 50 ml/min calculated by the Cockcroft-Gault Equation
Liver function
Total bilirubin <= 3 unless due to Gilbert's disease or hemolysis (total bilirubin > 3 is allowable if thought due to Gilbert's disease, hemolysis, or MPN disease); AST/ALT < 3 x ULN unless thought to be due to MPN disease process (AST/ALT > 3 is allowable if thought due to MPN disease)
Serum creatinine clearance >= 50 ml/min... Total bilirubin <= 3 unless due to Gilbert's disease or hemolysis... AST/ALT < 3 x ULN unless thought to be due to MPN disease process
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fred Hutch/University of Washington Cancer Consortium · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify